Navigation Links
InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update
Date:11/15/2011

the completion of the MASTER trial. This effort produced meaningful results in the third quarter, as we saw an 88% increase in shipments and a notable increase in revenues. We are also pleased to have received notice of our patent from the USPTO, bolstering the intellectual property protection for our first product. In addition, we remain focused on innovation, and plan to introduce additional products based on our mesh net technology. We are excited about our progress to date."

Third Quarter Financial ResultsFor the quarter ended September 30, 2011, total revenue was $2.0 million, an increase of 62.4% compared to the $1.2 million for the third quarter last year and a sequential increase of 91.0% compared to the $1.0 million for the second quarter of 2011. On a product delivery basis, shipments increased 87.8% during the third quarter of 2011 compared to the same period in 2010. Gross profit was $1.2 million, or 59.7% gross profit margin, compared to gross profit of $662,000, or 54.1% gross profit margin in the third quarter last year. Higher margins were due to higher average selling prices for the Company's stents and improved economies of scale. Total operating expenses were $3.3 million during the third quarter of 2011, compared to total operating expenses of $1.4 million in the same period in 2010. The majority of the increase was due to a $0.2 million, or 179%, increase in research and development expense, primarily related to investments in future products and the clinical validation of existing products as well as salaries, and a 175% increase in general and administrative expense, primarily related to $1.3 million non-cash charges for share-based compensation for one of the Company's new directors as well as public company, legal and investor relations expenses. Selling and marketing expenses remained relatively flat as compared to the same quarter in 2010.  

The Company reported a loss from operations of $2.2 million compared to a los
'/>"/>

SOURCE InspireMD
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
2. For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System
3. InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative
4. InspireMD Boosts MGuard Production Capacity
5. InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
6. InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference
7. InspireMD Increases Geographic Penetration; MGuard Stent is Now Available in India
8. InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week
9. InspireMD Announces Year-to-Date 2011 Progress
10. InspireMD Broadens Global Distribution Network; Signs Distributor for the Russian Federation
11. Sol J. Barer, Ph.D. Joins InspireMD Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Md. , Aug. 4, 2015 ... drug-free over-the-counter ActiPatch® Musculoskeletal Pain Therapy medical devices, ... users of its ActiPatch 7-day trial device has ... journal Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  ... the survey and submitted an assessment.  ...
(Date:8/4/2015)... 4, 2015 Research and Markets ( http://www.researchandmarkets.com/research/nl392k/alcohol ... Ethoxylate Market by Application (Household & Personal Care, Pharmaceutical, ... Forecasts to 2019" report to their offering. ... valued at $5,124.9 million in 2014 and is projected ... 2014 to 2019. The data mentioned in the report ...
(Date:8/4/2015)... Second Quarter 2015 Highlights: ... quarter of 2014 , Net earnings attributable to Team ... after adjustments , Diluted net earnings per share of ... 15.2% to $99.4 million 2015 Outlook: ... of 24.0% to 26.0%; Adjusted EBITDA margin remains between 10.5% ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 4Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 6Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 7Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 8Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 9Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 10Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 11Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 12Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 13Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 14Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 15Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 16Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 17Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 18Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 19Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 20Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 21Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 22Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 23Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 24Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 25Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 26Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 27Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 28Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 29Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 30Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 31Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 32Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 33
... Phase 2 Results of Perifosine in the Treatment of ... ... NEW YORK, June 2 Keryx Biopharmaceuticals,Inc. (Nasdaq: ... KRX-0401,(Perifosine) have been selected for both poster presentation and,publication ...
... June 2 Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) ... Phase III pivotal clinical trials of JZP-6,(sodium oxybate) for ... this trial is a key milestone in the JZP-6,program. ... trial in the fourth,quarter of 2008," said Samuel Saks, ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 2Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 3Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 4Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 5Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia 2Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia 3
(Date:8/4/2015)... ... August 04, 2015 , ... PerceptiMed, ... Richard Carmona, M.D., M.P.H., FACS, to its Board of Directors effective August 1, ... lives," Dr. Carmona said. "I strongly believe in the mission of the company ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... Local Food,” scheduled for Nov. 3 – 4, 2015, at UC San Diego, ... create new businesses, improve food access, and manage resources efficiently against the dueling ...
(Date:8/4/2015)... ... ... Many men are confused about the safety of testosterone replacement therapy. In ... voice of authority for men seeking accurate information about testosterone. , Renew Man™ ... in the safe and effective treatment of low testosterone. In recent years, the experts ...
(Date:8/4/2015)... ... August 04, 2015 , ... They say a picture is worth a thousand ... and medical art can be essential. StayWell, a health solutions company, announced today it ... solutions have been used by physicians and other health care providers for more than ...
(Date:8/4/2015)... ... August 04, 2015 , ... Discovia, a leading ... announced that John Munro, a 15-year veteran of the eDiscovery services industry, has ... , “I am thrilled to join Discovia at this important point in its ...
Breaking Medicine News(10 mins):Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3
... the sentencing of actor Sylvester Stallone came as an anti-climax ... Sydney. ,He was fined $2,975 for bringing banned ... of $10,000. ,A Customs search of his luggage ... February last had revealed 48 vials of the banned human ...
... of those suffering from AIDS came forth as hundreds of ... there to support them, gathered at a candlelight memorial ... AIDS Candlelight Memorial Day late Sunday saw more than 500 ... wearing white T-shirts and holding a candles. The third Sunday ...
... American bio-pharmaceutical major Gilead, which has entered into generic ... its HIV drug Viread, is hoping to get a ... made considerable progress in implementing our access programme and ... a pricing of $1 a day for the pill," ...
... According to a new study, repeated exposure to one person's ... shared opinions from multiple people. , ,This ... recipients sense of familiarity and in some cases gives a ... then it actually is. , ,In a series ...
... is on in the US to rein in sexual offenders ... safer for everyone. ,Social networking sites allow users ... and let them send messages to one another and, in ... MySpace had initially balked when attorneys general from eight states ...
... in the Shangdong province of eastern China have been afflicted ... has since been contained, state news agency Xinhua has reported. ... and another 393 people mostly children were still ... agency said, citing Bao Wenhui, the deputy director of the ...
Cached Medicine News:Health News:Steroid Scam: Sylvester Stallone Gets Away With a Light Punishment 2Health News:AIDS Victims, Supporters Gather in Bond of Hope 2Health News:Gilead's AIDS Drug Awaits Patent in India 2Health News:Repetition Is Like Chanting The More It is Heard the More You Believe It 2Health News:My Space Pressured into Sharing Data on Sex Offenders 2
... centrifuge is designed especially for ... cover with safety interlock switch, ... emissions, "hold" position for continuous ... motor, maximum stability and compact, ...
... The Rotanta 460 family ... extraordinary line that meets ... demands. They feature high ... Their state-of-the-art technology and ...
The Spinchron 15 centrifuge provides all the versatility and high capacity needed for today's full-service clinical lab needs. This centrifuge is available in a nonrefrigerated model with a speed up ...
... lens handle lets them hold the ... itself. Lenses and tints are shown ... white with literature holders on each ... black, red, or white marble, gray ...
Medicine Products: